Company Overview of Paradigm Ltd.
Paradigm Ltd. develops software-enabled solutions for the global oil and gas industry. The company offers seismic processing and imaging, interpretation and modeling, reservoir characterization, reservoir engineering, and data management and interoperability solutions, as well as well planning, drilling engineering, and geo-steering solutions. Its solutions help natural resources companies in assisting their exploration and production decisions by providing deeper insight into the subsurface. The company also offers formation evaluation software for the assessment of well integrity to ensure safe operations; and well schematics and production logging tools to assist with post-production form...
Two Memorial Plaza
Houston, TX 77024
Founded in 1987
Key Executives for Paradigm Ltd.
Chief Executive Officer, President and Director
Founder and Non-Executive Chairman
Chief Technology Officer of Interpretation and Modeling
Compensation as of Fiscal Year 2015.
Paradigm Ltd. Key Developments
Paradigm Releases Paradigm Geolog 7.4
Nov 20 15
Paradigm announced that, it has released Paradigm Geolog 7.4, the latest version of its Geolog formation evaluation software suite. Geolog 7.4 offers a rich set of new engineering functionalities that expand the product's reach into additional phases of the production cycle. This release also extends third-party connectivity, including support for Petrel 2015, enabling users to bring the power of Geolog into workflows based in other products. Geolog 7.4 enhances the solution for engineers with tools to enable an independent assessment of well integrity, critical to ensuring safe operations; and new well schematics and production logging tools to assist with post-production formation evaluation. In addition, a new, full-functioned geomechanics module offers a comprehensive series of calculations and interactive tools for assessing mechanical conditions around the wellbore, resulting in a better understanding of the reservoir. New reservoir characterization plots enable the estimation of reservoir flow properties from log data. And the Geolog pore pressure prediction functionality is now available in a single integrated workflow, for improved efficiency.
Paradigm Announces Molecular Profiling Collaboration for Study of Altiratinib in Genomically Defined Cancer Patients
Aug 19 15
Paradigm announced a pharmaceutical services relationship with Deciphera Pharmaceuticals for a phase I clinical study of Altiratinib in molecularly defined cancers driven by either MET or TRK genomic alterations including lung cancer, gastric cancer, renal cancer, and glioblastoma multiforme (GBM). Paradigm will use its Paradigm Cancer Diagnostic (PCDx) panel's advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to Deciphera's Altiratinib, a MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor, which has been granted an Orphan Drug Designation for GBM by the FDA. PCDX is also broadly available to assist cancer patients and their oncologists find actionable FDA approved therapies.
Paradigm Expands Access to PCDx Medicine Service by Signing Contract with Three Rivers Provider Network
Aug 7 15
Paradigm has signed an agreement with Three Rivers Provider Network Inc. Under the terms of the agreement, Paradigm's Cancer Diagnostic Test (PCDx) will be available to more than 15 million US members of Three Rivers Provider Network. PCDx™ is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with information to allow a more targeted, approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patient's tumor's DNA, RNA & protein.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|